Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Grande Portage Resources (V.GPG) Initiates Sensor-Based Ore Sorting Testwork (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Passage Bio Inc PASG

Healthcare Biotechnology
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional... see more

Recent & Breaking News (NDAQ:PASG)

Moore Kuehn, PLLC Encourages Investors of Passage Bio, Inc. to Contact Law Firm

Newsfile November 30, 2021

Passage Bio Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 19, 2021

Passage Bio to Present at Guggenheim 3rd Annual Neuro/Immunology Conference

GlobeNewswire November 9, 2021

Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights

GlobeNewswire November 4, 2021

Passage Bio to Report Third Quarter 2021 Financial Results on November 4, 2021

GlobeNewswire October 28, 2021

Passage Bio to Participate in Upcoming October Conferences

GlobeNewswire September 27, 2021

Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 17, 2021

Passage Bio Announces Maxine Gowen, Ph.D., as Chairwoman of the Board of Directors

GlobeNewswire September 7, 2021

Passage Bio to Present at Citi 16th Annual BioPharma Virtual Conference

GlobeNewswire September 2, 2021

Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 27, 2021

Passage Bio Reports Second Quarter 2021 Financial Results and Provides Recent Business Highlights

GlobeNewswire August 5, 2021

Passage Bio Mourns the Sudden Passing of Chairman of the Board Tadataka Yamada, M.D.

GlobeNewswire August 4, 2021

Passage Bio to Present at 12th Annual Wedbush PacGrow Healthcare Conference

GlobeNewswire August 4, 2021

Passage Bio to Report Second Quarter 2021 Financial Results on August 5, 2021

GlobeNewswire July 29, 2021

Passage Bio Announces Inducement Award for Newly Appointed Chief Commercial Officer Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 21, 2021

Passage Bio Announces Key Executive Appointments

GlobeNewswire July 19, 2021

Derrell D. Porter, M.D., Elected to Board of Directors of Passage Bio

GlobeNewswire June 1, 2021

Passage Bio to Participate in Upcoming June Investor Conferences

GlobeNewswire May 26, 2021

Passage Bio Announces Pre-Clinical Data Presentation at Annual ASGCT Meeting

GlobeNewswire May 11, 2021

Passage Bio to Host Virtual R&D Event on May 17

GlobeNewswire May 10, 2021